Your browser doesn't support javascript.
loading
Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection.
Sibley, Laura; White, Andrew D; Sarfas, Charlotte; Gullick, Jennie; Gleeson, Fergus; Lanni, Faye; Clark, Simon; Rayner, Emma; Ferrer-Bazaga, Santiago; Ortega-Muro, Fatima; Alameda, Laura; Rullas, Joaquin; Sousa, Veronica; Martinez, Marisa; Angulo-Barturen, Inigo; Garcia, Adolfo; Vaquero, Juan José; Pertinez, Henry E; Davies, Geraint; Dennis, Mike; Williams, Ann; Sharpe, Sally.
Afiliación
  • Sibley L; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • White AD; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Sarfas C; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Gullick J; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Gleeson F; Department of Oncology, Medical Sciences Division, Churchill Hospital, Oxford OX3 7DQ, UK.
  • Lanni F; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Clark S; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Rayner E; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Ferrer-Bazaga S; Departmento de Bioingenieria, Universidad Carlos III de Madrid, 28903 Madrid, Spain.
  • Ortega-Muro F; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain.
  • Alameda L; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain.
  • Rullas J; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain.
  • Sousa V; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain.
  • Martinez M; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain.
  • Angulo-Barturen I; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain.
  • Garcia A; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain.
  • Vaquero JJ; Departmento de Bioingenieria, Universidad Carlos III de Madrid, 28903 Madrid, Spain.
  • Pertinez HE; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GX, UK.
  • Davies G; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GX, UK.
  • Dennis M; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Williams A; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
  • Sharpe S; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
Pharmaceutics ; 14(12)2022 Nov 30.
Article en En | MEDLINE | ID: mdl-36559163
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Pharmaceutics Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Pharmaceutics Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza